We are pleased to share that our presentation at the Crohn’s & Colitis Congress 2026, held January 22–24 in Las Vegas, was recognized with a “Poster of Distinction” award (attached photos). The conference was organized by Crohn’s & Colitis Foundation and the American Gastroenterology Association and had ~2,000 attendees, primarily from US universities and big pharma.
The honored poster was presented by Allan Pantuck, MD, MS, FACS and was titled “Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of ATH-063: A Novel, Oral, Artificial Intelligence-Generated Drug for Inflammatory Bowel Disease.” It highlighted encouraging Phase 1 human trial results with ATH-063 and addressed its potential relevance in Inflammatory Bowel Diseases (IBD).
The Poster of Distinction designation is awarded to a select group of presentations based on scientific merit and clinical relevance. We believe that this recognition reflects the quality of the study design, the positive results reported, and the growing interest in innovative, AI-enabled approaches to drug discovery and development.
We view this acknowledgment as another validation of our scientific strategy and an encouraging step as we continue advancing ATH-063 through clinical development into the recently authorized phase 2 study.